These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23928514)

  • 1. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
    Spear SA; Burns SS; Oblinger JL; Ren Y; Pan L; Kinghorn AD; Welling DB; Chang LS
    Otol Neurotol; 2013 Oct; 34(8):1519-27. PubMed ID: 23928514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
    Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
    Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
    Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
    Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
    Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
    Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.
    Mercado-Pimentel ME; Miller C; Rolph DN; Villalobos EF; Dunn AM; Mohan PM; Igarashi S; Liu X; Yrun-Duffy M; Patel NK; Read CM; Francis RH; Lane AI; Murugesh S; Jacob A
    Otol Neurotol; 2017 Jan; 38(1):139-146. PubMed ID: 27755359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
    Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
    Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells.
    Wang J; Lv P
    Bioengineered; 2021 Dec; 12(1):755-762. PubMed ID: 33622177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
    Burns SS; Chang LS
    Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.
    Curic S; Wu Y; Shan B; Schaaf C; Utpadel D; Lange M; Kuhlen D; Perone MJ; Arzt E; Stalla GK; Renner U
    J Neurooncol; 2013 Jul; 113(3):385-96. PubMed ID: 23666203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.
    Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P
    CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
    Bhattacharyya S; Oblinger JL; Beauchamp RL; Yin Z; Erdin S; Koundinya P; Ware AD; Ferrer M; Jordan JT; Plotkin SR; Xu L; Chang LS; Ramesh V
    Neuro Oncol; 2023 Sep; 25(9):1617-1630. PubMed ID: 36806881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
    Johnson MD; O'Connell MJ; Walter K
    BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
    Bassiri K; Ferluga S; Sharma V; Syed N; Adams CL; Lasonder E; Hanemann CO
    EBioMedicine; 2017 Feb; 16():76-86. PubMed ID: 28126595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group I Paks as therapeutic targets in NF2-deficient meningioma.
    Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
    Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of cucurbitacin B on cell proliferation and apoptosis in Hep-2 cells].
    Liu T; Zhang M; Deng Y; Zhang H; Sun C; Yang X; Ji W
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 May; 22(9):403-7. PubMed ID: 18652313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
    James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
    Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.